A recent pooled analysis of several large clinical studies evaluating first-line systemic treatment based on a combination of chemotherapy and anti-EGFR agents (aEGFR-ChT) found that survival benefit is driven by patients with LCC [8,16]). Here, EGFR is linked to leukoencephalopathy with calcifications and cysts.